Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

GLP-1 agonists

This page shows the latest GLP-1 agonists news and features for those working in and with pharma, biotech and healthcare.

Novo's semaglutide beats Lilly's Trulicity in diabetes contest

Novo's semaglutide beats Lilly's Trulicity in diabetes contest

Novo Nordisk says its once-weekly GLP-1 agonist semaglutide could become a "new standard" in type 2 diabetes after beating rival Eli Lilly's Trulicity (dulaglutide) in a phase III ... Trulicity's growth stems from its once-weekly dosing, which has proved

Latest news

  • Sanofi's lixisenatide is back under FDA review Sanofi's lixisenatide is back under FDA review

    In the interim Novo Nordisk's rival Victoza (liraglutide) has firmly established itself at the top of the GLP-1 agonist tree, with sales of around $2bn a year. ... Meanwhile, new GLP-1 agonists that require dosing just once a week - including Eli Lilly's

  • Sanofi plans LixiLan filings after positive phase III trial Sanofi plans LixiLan filings after positive phase III trial

    If approved it will compete in the market with Novo Nordisk's insulin/GLP-1 agonist product Xultophy (insulin degludec/liraglutide), which was launched earlier this year. ... Jefferies' Peter Wellford indicating earlier this year that the basal

  • Novo Nordisk's Victoza fails type 1 diabetes trial Novo Nordisk's Victoza fails type 1 diabetes trial

    The year-long trial involved almost 1, 400 patients who were given one of three doses of long-acting GLP-1 agonist liraglutide or placebo, given once-daily by subcutaneous injection - ... episodes. The concept of combining insulin with GLP-1 agonists has

  • Type 2 diabetes market set to hit $39bn by 2021 Type 2 diabetes market set to hit $39bn by 2021

    In particular its new report points to three classes of drugs: dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 (GLP-1) receptor agonists and sodium–glucose cotransporter 2 inhibitors. ... Newer versions of glucagon-like peptide-1 (GLP

  • Receptos rejected AZ takeover bid, say sources Receptos rejected AZ takeover bid, say sources

    Receptos' main asset is oxanimod (RPC1063), a sphingosine 1-phosphate 1 receptor (S1P1R) modulator in phase III testing for multiple sclerosis and phase II for Crohn's disease.  . ... small-molecule agonists of glucagon-like peptide-1 (GLP-1), which

More from news
Approximately 8 fully matching, plus 34 partially matching documents found.

Latest Intelligence

  • Deal Watch table for January 2015 Deal Watch table for January 2015

    Licence collaboration agreement. 1, 110. Janssen/ Depomed. Nucynta [tapentadol] franchise including extended release tablets and oral solutions. ... Asset acquisition. 142.  Amunix/Naia. To develop glucagon peptide agonists GLP-1-XTEN and GLP-2-XTEN in

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cuttsy + Cuttsy

How do you understand what patients really need, without actually living their lives? How do you walk in someone else’s...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Quick links

Infographics

Multimedia